Halozyme Therapeutics Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
14 Aug 24 | SellUS$1,689,294 | Matthew Posard | Individual | 29,881 | US$57.70 | |
12 Jun 24 | SellUS$1,006,300 | Matthew Posard | Individual | 20,000 | US$50.62 |
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
State or Government | 60,275 | 0.0465% |
Individual Insiders | 1,274,233 | 0.983% |
Institutions | 128,227,205 | 99% |
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
17,619,937 | US$789.5m | 0% | 0.01% | |||
12,895,096 | US$577.8m | 0.11% | 0.01% | |||
6,633,688 | US$297.3m | 14.1% | 0.01% | |||
4,063,367 | US$182.1m | 0.58% | 3.85% | |||
3,408,341 | US$152.7m | -3.97% | 0.05% | |||
3,133,412 | US$140.4m | -15.7% | 0.11% | |||
3,060,131 | US$137.1m | 1.02% | 0.01% | |||
3,010,825 | US$134.9m | -2.17% | 0.16% | |||
2,525,184 | US$113.2m | -2.38% | 0.01% | |||
2,433,579 | US$109.0m | 446% | 0.74% | |||
2,010,655 | US$90.1m | -3.83% | 1.16% | |||
1,969,169 | US$88.2m | 76.9% | 0.13% | |||
1,885,765 | US$84.5m | -0.63% | 0.01% | |||
1,773,397 | US$79.5m | -0.79% | 0.01% | |||
1,762,261 | US$79.0m | -19.2% | 0.65% | |||
1,682,154 | US$75.4m | -6.34% | 0.01% | |||
1,656,213 | US$74.2m | -15.6% | 0.02% | |||
1,550,736 | US$69.5m | -34.5% | 0.05% | |||
1,539,153 | US$69.0m | 6.72% | 0.02% | |||
1,464,787 | US$65.6m | 223% | 0.03% | |||
1,359,730 | US$60.9m | -4.37% | 0.84% | |||
1,270,521 | US$56.9m | -2.39% | 0.01% | |||
1,269,827 | US$56.9m | 50.1% | 0.49% | |||
1,216,161 | US$54.5m | 0% | no data | |||
1,082,359 | US$48.5m | 42.1% | 0.01% |